Skip to main content

LCD L33417: Allergy Skin Testing

LCD L33417, Allergy Skin Testing, is the Local Coverage Determination that Palmetto GBA applies to claims from 7 states (AL, GA, NC, SC, TN, VA, WV), effective 2021-04-15 and first in force 2015-10-01. The policy text runs 706 words, and its billing and coding article A56559 lists 420 ICD-10-CM codes that support medical necessity for 4 procedure codes. No other contractor publishes a policy with this title.

QuickIntell editorial content · Legacy registry date · Review not verified

Data effective
Data currency: Medicare Coverage Database LCD export release of September 24, 2026 (effective September 20, 2026). Next CMS release: weekly (Thursdays) for the MCD.
Contractor
Palmetto GBA
States and territories
7
AL GA NC SC TN VA WV
Revision effective
2021-04-15
Original effective
2015-10-01
Policy text
706 words
Covered ICD-10 codes (articles)
420

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L33417
ContractContractorTypeStates
11202Palmetto GBAA and B and HHH MACSC
11302Palmetto GBAA and B and HHH MACVA
11402Palmetto GBAA and B and HHH MACWV
11502Palmetto GBAA and B and HHH MACNC
10112Palmetto GBAA and B MACAL
10212Palmetto GBAA and B MACGA
10312Palmetto GBAA and B MACTN

Billing and coding: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A56559 (Billing and Coding: Allergy Skin Testing) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown.

A56559: Billing and Coding: Allergy Skin Testing (Billing and Coding, effective 2025-10-01)

Covered ICD-10-CM codes
420
3 groups
Non-covered ICD-10-CM codes
0
Procedure codes listed
4
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A56559
ICD-10-CMDescription (FY2027)
H10.11—
H10.12—
H10.13—
H10.411—
H10.412—
H10.413—
H10.419—
H10.44—
H10.45—
H16.261—
H16.262—
H16.263—
J30.0—
J30.1—
J30.2—
J30.5—
J30.81—
J30.89—
J30.9—
J31.0—
J32.0—
J32.1—
J32.2—
J32.3—

Procedure codes: 95004, 95017, 95018, 95024.

Coverage indications, limitations and medical necessity

Allergy skin testing is a clinical procedure that is used to evaluate an immunologic response to allergenic material. The need for testing and interpretation of test findings must be correlated with signs and symptoms of possible allergies as determined by a complete history and physical examination of the patient. The number and type of antigens used for testing must be chosen judiciously given the patient’s presentation and the tester’s clinical judgment.

Allergy testing is covered when a patient presents with clinically significant allergic history or symptoms that are not controllable by empiric conservative therapy. For Medicare to cover allergy testing, all of the following criteria must be met:

• Testing must correlate specifically to the patient’s history and physical findings.

• The test technique and/or allergens tested must have proven efficacy demonstrated through scientifically valid medical studies published in peer-reviewed literature.

• Allergy testing must be performed on patients whose environment provides the reasonable probability of exposure to the specific antigen tested.

Percutaneous testing is the usual preferred method for allergy testing. Medicare covers percutaneous (scratch, prick or puncture) testing when documented IgE-mediated reactions occur to any of the following:

• Inhalants

• Foods

• Hymenoptera (stinging insects)

• Specific drugs (penicillins and macromolecular agents)

In selected patients, intradermal testing for the same antigen may be necessary to test persons whose percutaneous test was negative. For intradermal testing, the clinician should narrow the area of investigation so that the minimal number of skin tests necessary for diagnosis is performed. Medicare covers intradermal (intracutaneous) testing when documented IgE-mediated reactions occur to any of the following:

• Inhalants

• Hymenoptera (stinging insects)

• Specific drugs (penicillins and macromolecular agents)

Retesting with the same antigen(s) should rarely be necessary within a 3-year period. Exceptions include young children with negative skin tests, or older children and adults with negative skin tests in the face of persistent symptoms. Routine repetition of skin tests is not indicated (i.e., annually). If under specific circumstances, extensive repeat testing is required within a 3-year period, those circumstances must be clearly documented in the medical record including an explanation as to why the original testing is unacceptable.

Percutaneous testing for food allergens is covered for patients with a clinical presentation suggestive of significant IgE mediated food allergy. Such patients will have presented with signs and symptoms of such conditions as angioedema, urticaria or anaphylaxis after ingestion of specific foods. Testing for food allergies in patients who present with significant respiratory symptoms alone may be required in certain instances.

The following allergy testing is non-covered by Medicare:

• Provocative and neutralization testing and neutralization therapy of food allergies (sublingual, intracutaneous and subcutaneous) are excluded from Medicare coverage because available evidence does not show these tests and therapies are effective

• Qualitative multiallergen screens have insufficient literature demonstrating clear-cut clinical utility and are, therefore, non-covered

• Late reactions occurring with allergenic extracts are of unclear clinical significance and are, therefore, non-covered

• Intradermal testing for food allergens

• Food allergen testing for patients who present with respiratory symptoms other than wheezing and asthma

• Food allergen testing for patients who present with gastrointestinal symptoms suggestive of food intolerance

• Skin endpoint testing

• Allergy testing for antigens for which no clinical efficacy is documented in peer-reviewed literature. Such antigens include but are not limited to the following:

• Grain mill dust (pollen grains of cereals/related crops are large; they do not become airborne)

• Tobacco smoke (no component has ever been shown to be a respiratory allergen)

• Orris root (almost never used in cosmetics these days; test adds nothing to evaluation)

• Dandelion (non-allergenic; no pollen produced)

• Marigold (non-allergenic; no airborne pollen produced)

• Honeysuckle (non-allergenic; non-significant airborne pollen produced)

Allergy testing for certain antigens is covered only when performed on patients whose environment provides the reasonable probability of their exposure to antigens tested. Such antigens include, but are not limited to the following:

• Tobacco leaf for tobacco workers

• Pyrethrum for florists (non-allergenic; found in some insecticides; cross-reacts strongly with ragweed)

• Golden rod for florists (pollen not carried by wind)

• Soybean dust for workers in food processing plants

• Wool for patients exposed to sheep or unprocessed wool (processed wool is non-allergenic)

Summary of evidence (opening)

N/A

the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2015-10-01
Current revision effective
2021-04-15
Last reviewed by the contractor
2021-03-04
MCD version
40
Derived from
L31774

The contractor lists 4 National Coverage Determinations as related: NCD 110.11 Food Allergy Testing and Treatment, NCD 110.12 Challenge Ingestion Food Testing, NCD 110.13 Cytotoxic Food Tests, NCD 110.9 Antigens Prepared for Sublingual Administration. Where an NCD speaks, it controls; the LCD can only address what the NCD leaves open.

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line, and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Palmetto GBA hub lists every other active policy from the same contractor.

Frequently asked questions

What does LCD L33417 cover?

Allergy skin testing is a clinical procedure that is used to evaluate an immunologic response to allergenic material. The need for testing and interpretation of test findings must be correlated with signs and symptoms of possible allergies as determined by a complete history and physical examination of the patient. The number and type of antigens used for testing must be chosen judiciously given the patient’s… The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database export of September 24, 2026.

Which states does LCD L33417 apply to?

Palmetto GBA applies it to Medicare claims in AL, GA, NC, SC, TN, VA, WV. A Local Coverage Determination binds only the contractor that wrote it; the same service in another jurisdiction is judged under that contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L33417?

The companion billing and coding article A56559 lists 420 ICD-10-CM codes in 3 groups that support medical necessity; the first 24 appear on this page and the complete list is in the article on cms.gov.

How do I appeal a denial under LCD L33417?

The remittance carries claim adjustment reason code 50 with remark code N115, naming the LCD. Compare the documented indication with the policy's covered indications and the article's diagnosis list, then file a redetermination within 120 days with the record attached; if the service genuinely falls outside the policy, the patient can be billed only when a valid Advance Beneficiary Notice was obtained before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-10-02. Verify against the primary file before billing or contracting decisions.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.